Activating mutations in EGFR are characteristic of patients with lung cancer who have high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. The randomized IPASS ...

Kim's team revealed that once COVID-19 invades human cells, it quickly modifies the structure and function ... that the virus ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in ...